|  | 
| MechanismPTP1B modulators | 
|  | 
|  | 
|  | 
| Inactive Indication- | 
| Drug Highest PhasePhase 1 | 
| First Approval Ctry. / Loc.- | 
| First Approval Date- | 
A Multiple Dose, Randomized, Placebo-controlled, Dose-escalating Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered MD-18 for Healthy Subjects with Overweight or Obesity
A Multiple Dose, Randomized, Placebo-controlled, Dose-escalating Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered MD-18 for healthy subjects with overweight or obesity
 / Active, not recruitingPhase 1 A Single Center, Single Dose, Double-blind, Randomized, Placebo-Controlled, Dose-Escalating Study to Evaluate Safety, Tolerability and Pharmacokinetics of Subcutaneously Administered MD-18 in Healthy Subjects.
A Single Center, Single Dose, Double-blind, Randomized, Placebo-controlled Dose-Escalating Study to Evaluate Safety, Tolerability and Pharmacokinetics of Subcutaneously Administered MD-18 in healthy subjects.
100 Clinical Results associated with Cohen Global Ltd.
0  Patents (Medical) associated with Cohen Global Ltd.
100 Deals associated with Cohen Global Ltd.
100 Translational Medicine associated with Cohen Global Ltd.